Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Erber Group was an Austrian life-science-oriented company focused on animal nutrition and health and on food and feed safety diagnostics. Its main businesses were Biomin, which provided mycotoxin risk management, gut health performance solutions, probiotics, and phytogenic feed additives for livestock, and Romer Labs, which provided diagnostic solutions for food and feed safety. In 2020, Royal DSM completed the acquisition of Erber Group's Biomin and Romer Labs businesses for an enterprise value of EUR 980 million, while smaller units including Sanphar and EFB were excluded from the transaction. As a result, Erber Group no longer operates as an independent active company, although its businesses and technologies continue under successor ownership structures.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Erber Group.